Monmouthshire

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

Retrieved on: 
목요일, 11월 3, 2022
MSD, Protein, Merck, Food, Regulation of tobacco by the U.S. Food and Drug Administration, Biology, GLOBE, Breakthrough therapy, Safety, Neoplasm, Merck & Co., Securities Exchange Act of 1934, Nasdaq, IO, CEO, Securities Act of 1933, Opinion, PD-L1, Data, Medicine, Forward-looking statement, Drug Quality and Security Act, Pembrolizumab, IDO, Toxicity, Melanoma, Monmouthshire, Patient, Pharmaceutical industry

The proof-of-concept trial will include patients with resectable tumors in at least two indications.

Key Points: 
  • The proof-of-concept trial will include patients with resectable tumors in at least two indications.
  • We are pleased to extend our collaboration with Merck into this new exploration of IO102-IO103 in combination with pembrolizumab in earlier, neoadjuvant and adjuvant settings, said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • Under the terms of the agreement, IO Biotech will sponsor the Phase 2 trial and Merck will supply pembrolizumab.
  • IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates.

IO Biotech to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
월요일, 10월 31, 2022
Securities Act of 1933, CEO, Forward-looking statement, IO, Cancer, Investor, Securities Exchange Act of 1934, GLOBE, Monmouthshire, Pembrolizumab, IDO, CFO, Review, PD-L1, Nasdaq, Conference, Vaccine

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.

Key Points: 
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.
  • IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates.
  • IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).
  • Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

IO Biotech Announces Appointment of New Chief Financial Officer

Retrieved on: 
목요일, 10월 13, 2022
Euronext, Securities Act of 1933, Sale, Medicine, Science, Biotechnology, Drug development, IO, Genencor, Bentley University, AMAG Pharmaceuticals, Nasdaq, Fortune 500, Cancer, Monmouthshire, Salem State University, Securities Exchange Act of 1934, BV, GLOBE, Forward-looking statement, IDO, FDA, PD-L1, Management, Sanofi

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, today announced the appointment of Amy Sullivan as the companys new Chief Financial Officer.

Key Points: 
  • NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, today announced the appointment of Amy Sullivan as the companys new Chief Financial Officer.
  • We are pleased to welcome Amy to the executive team, said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech.
  • Her financial prowess and successful track record guiding biotechnology companies through significant organizational growth will be an invaluable addition to IO Biotech.
  • Ms. Sullivan joins IO Biotech from TABA, BV, where she served as chief financial officer.

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
수요일, 10월 5, 2022
Time, Drug Quality and Security Act, Science, SITC, Vaccine, Patient, IO, Herlev Hospital, Securities Act of 1933, Immunotherapy, Nasdaq, Monmouthshire, Cancer, Society for Immunotherapy of Cancer, Nivolumab, Society, Securities Exchange Act of 1934, GLOBE, EST, Forward-looking statement, Center, IDO, FDA, PD-L1, Pharmaceutical industry, Communications satellite

The invited oral presentation will provide an update on the Phase 1/2 study (MM1636) with IO102-103 in combination with nivolumab for metastatic melanoma.

Key Points: 
  • The invited oral presentation will provide an update on the Phase 1/2 study (MM1636) with IO102-103 in combination with nivolumab for metastatic melanoma.
  • The two posters will discuss preclinical work on the next two candidates in the IO Biotech pipeline, which target the immunosuppressive effects of Arginase 1 and transforming growth factor beta 1 (TGF-1).
  • The T-win platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms.
  • Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
화요일, 9월 6, 2022
CEO, Securities Exchange Act of 1934, Securities Act of 1933, Morgan, Morgan Stanley, IO, GLOBE, Conference, Nasdaq, Investor, Monmouthshire, PD-L1, IDO, Forward-looking statement, Vaccine

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.

Key Points: 
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.
  • IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates.
  • IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).
  • Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

IO Biotech Announces Second Quarter Results for 2022

Retrieved on: 
목요일, 8월 11, 2022
Drug Quality and Security Act, Monmouthshire, IO, ASCO, Forward-looking statement, GLOBE, American Society of Clinical Oncology, Annual general meeting, Securities Exchange Act of 1934, Clinical, Clinical trial, PD-L1, Society, Merck, NSCLC, Patient, Pembrolizumab, Safety, SCCHN, Â, Research, Chemistry, Securities Act of 1933, Melanoma, Nasdaq, IDO, Consultant, Pharmaceutical industry, Cryptocurrency

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced today financial results for the quarter ending June 30, 2022.

Key Points: 
  • NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced today financial results for the quarter ending June 30, 2022.
  • We expect to receive preliminary data in one indication in the second half of 2022, and additional data in 2023.
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.
  • Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

IO Biotech to Participate in the 2022 BIO International Convention

Retrieved on: 
월요일, 6월 6, 2022
IDO, IO, Monmouthshire, Securities Exchange Act of 1934, San Diego Convention Center, Securities Act of 1933, Forward-looking statement, Nasdaq, GLOBE, PD-L1, Vaccine

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced today that the company will be participating at the 2022 BIO International Convention, taking place June 13 16, 2022, at the San Diego Convention Center in San Diego, California.

Key Points: 
  • NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced today that the company will be participating at the 2022 BIO International Convention, taking place June 13 16, 2022, at the San Diego Convention Center in San Diego, California.
  • Panel details are summarized below:
    IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.
  • IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates.
  • Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

Retrieved on: 
목요일, 5월 26, 2022
UBC, Nasdaq, Patient, IDO, IO, Society, American Society of Clinical Oncology, NSCLC, PD-L1, Securities Act of 1933, Securities Exchange Act of 1934, SCCHN, Forward-looking statement, Neck, ASCO, Monmouthshire, Head, Protein, GLOBE, Vaccine

The meeting will be held in-person and virtually June 3-7, 2022 in Chicago.

Key Points: 
  • The meeting will be held in-person and virtually June 3-7, 2022 in Chicago.
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.
  • IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates.
  • Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

IO Biotech to Participate in the Jefferies Healthcare Conference

Retrieved on: 
월요일, 5월 23, 2022
CEO, Company, Nasdaq, IDO, IO, Time, Investor, PD-L1, Securities Act of 1933, Securities Exchange Act of 1934, Conference, Forward-looking statement, Monmouthshire, GLOBE, Vaccine

Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech will be available to meet with investors in-person on a one-on-one basis throughout the conference.

Key Points: 
  • Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech will be available to meet with investors in-person on a one-on-one basis throughout the conference.
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.
  • IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).
  • Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

Retrieved on: 
수요일, 5월 18, 2022
CEO, NEW, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, BTD, Nasdaq, Patient, IDO, IO, ORR, Clinical trial, Merck, PD-L1, FDA, Securities Act of 1933, Pembrolizumab, Securities Exchange Act of 1934, Forward-looking statement, Drug Quality and Security Act, Monmouthshire, CMO, Biomarker, Breakthrough therapy, Mab, Melanoma, GLOBE, Pharmaceutical industry

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has dosed the first patient in its Phase 3 IOB-013 / KN-D18 trial (NCT05155254).

Key Points: 
  • The IOB-013 / KN-D18 trial seeks to evaluate IO Biotechs lead candidate, IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 (programmed death receptor-1) therapy, in patients with previously untreated, unresectable or metastatic (advanced) melanoma.
  • This is a strong manifestation of our broad, late-stage development program, said Mai-Britt Zocca, Ph.D., President and CEO IO Biotech.
  • Executing this clinical trial builds on IO Biotechs recent momentum including financial, international, and organizational expansion.
  • Although therapies are available to treat metastatic melanoma, the clinical outcomes for patients with advanced disease remain poor and novel therapeutic options are desperately needed, said Eva Ehrnrooth, M.D., Ph.D., CMO of IO Biotech.